These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 29452503)
21. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Polónia A; Leitão D; Schmitt F Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674 [TBL] [Abstract][Full Text] [Related]
22. ASCO update on lymphoma. Fridrik MA Memo; 2017; 10(4):218-219. PubMed ID: 29250199 [TBL] [Abstract][Full Text] [Related]
23. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Van Poznak C; Somerfield MR; Barlow WE; Biermann JS; Bosserman LD; Clemons MJ; Dhesy-Thind SK; Dillmon MS; Eisen A; Frank ES; Jagsi R; Jimenez R; Theriault RL; Vandenberg TA; Yee GC; Moy B J Clin Oncol; 2017 Dec; 35(35):3978-3986. PubMed ID: 29035643 [TBL] [Abstract][Full Text] [Related]
24. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. Bennett CL; Somerfield MR; Pfister DG; Tomori C; Yakren S; Bach PB; J Clin Oncol; 2003 Mar; 21(5):937-41. PubMed ID: 12610197 [TBL] [Abstract][Full Text] [Related]
25. The ASH/ASCO clinical guidelines on the use of erythropoietin. Lichtin A Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917 [TBL] [Abstract][Full Text] [Related]
26. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Hillner BE; Ingle JN; Chlebowski RT; Gralow J; Yee GC; Janjan NA; Cauley JA; Blumenstein BA; Albain KS; Lipton A; Brown S; J Clin Oncol; 2003 Nov; 21(21):4042-57. PubMed ID: 12963702 [TBL] [Abstract][Full Text] [Related]
27. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166 [TBL] [Abstract][Full Text] [Related]
28. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171 [TBL] [Abstract][Full Text] [Related]
29. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines. Qian XL; Wen HY; Yang YL; Gu F; Guo XJ; Liu FF; Zhang L; Zhang XM; Fu L Breast Cancer Res Treat; 2016 Aug; 159(1):31-9. PubMed ID: 27455837 [TBL] [Abstract][Full Text] [Related]
31. Use of Bisphosphonates in the Treatment of Multiple Myeloma. McCloskey EV; Libretto SE Hematology; 1998; 3(4):291-8. PubMed ID: 27413881 [TBL] [Abstract][Full Text] [Related]
32. [Bisphosphonates in the treatment of multiple myeloma]. Stajszczyk M Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045 [TBL] [Abstract][Full Text] [Related]
33. Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline. Yeh Y; Slovik D; Carter D; Clapp M; Churchill W; Reddy P J Clin Pharm Ther; 2011 Jun; 36(3):342-7. PubMed ID: 21545613 [TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates in the prevention and treatment of bone metastases. Ramaswamy B; Shapiro CL Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853 [TBL] [Abstract][Full Text] [Related]
35. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. Bloomfield DJ J Clin Oncol; 1998 Mar; 16(3):1218-25. PubMed ID: 9508210 [TBL] [Abstract][Full Text] [Related]
36. ASCO 2006 Update of the Breast Cancer Follow-Up and Management Guideline in the Adjuvant Setting. J Oncol Pract; 2006 Nov; 2(6):317-318. PubMed ID: 29447564 [No Abstract] [Full Text] [Related]
37. Clinical Practice Guideline: Otitis Media with Effusion (Update). Rosenfeld RM; Shin JJ; Schwartz SR; Coggins R; Gagnon L; Hackell JM; Hoelting D; Hunter LL; Kummer AW; Payne SC; Poe DS; Veling M; Vila PM; Walsh SA; Corrigan MD Otolaryngol Head Neck Surg; 2016 Feb; 154(1 Suppl):S1-S41. PubMed ID: 26832942 [TBL] [Abstract][Full Text] [Related]
38. [Biphosphonates as directed therapy in bone metastases]. Basić-Cabaravdić H Med Arh; 2003; 57(1):53-7. PubMed ID: 12693348 [TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Croucher PI; Shipman CM; Van Camp B; Vanderkerken K Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581 [TBL] [Abstract][Full Text] [Related]
40. Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. J Oncol Pract; 2009 May; 5(3):127-129. PubMed ID: 29452038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]